Transcatheter procedures have expanded our treatment options in patients with tricuspid regurgitation and high surgical risk. In tricuspid regurgitation, the first randomized controlled trial (TRILUMINATE pivotal) failed to demonstrate a prognostic benefit.
However, several registries and site-collected data indicate a remarkable clinical benefit in patients undergoing transcatheter tricuspid valve treatment.
The aim of the research topic is to expand our understanding of clinical improvements in patients with tricuspid regurgitation:
1. How can we assess clinical improvement more accurately than by asking for NYHA?
2. Does clinical improvement correlate with cardiac remodeling and changes in hemodynamics?
3. Is there a difference of clinical advantage with regard to the used treatment approach for tricuspid regurgitation?
4. How can we improve patient and device selection?
5. When is late, too late?
The scope of this Research Topic is to answer the stated research questions by original research articles and to provide an overview on currently available treatment options in transcatheter tricuspid valve procedures.
Keywords:
atrioventricular valve diseases, tricuspid regurgitation, transcatheter therapy, structural heart diseases, heart
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Transcatheter procedures have expanded our treatment options in patients with tricuspid regurgitation and high surgical risk. In tricuspid regurgitation, the first randomized controlled trial (TRILUMINATE pivotal) failed to demonstrate a prognostic benefit.
However, several registries and site-collected data indicate a remarkable clinical benefit in patients undergoing transcatheter tricuspid valve treatment.
The aim of the research topic is to expand our understanding of clinical improvements in patients with tricuspid regurgitation:
1. How can we assess clinical improvement more accurately than by asking for NYHA?
2. Does clinical improvement correlate with cardiac remodeling and changes in hemodynamics?
3. Is there a difference of clinical advantage with regard to the used treatment approach for tricuspid regurgitation?
4. How can we improve patient and device selection?
5. When is late, too late?
The scope of this Research Topic is to answer the stated research questions by original research articles and to provide an overview on currently available treatment options in transcatheter tricuspid valve procedures.
Keywords:
atrioventricular valve diseases, tricuspid regurgitation, transcatheter therapy, structural heart diseases, heart
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.